{"id":"placebo-tablets-per-os","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (symptom improvement without active drug)"},{"rate":null,"effect":"Adverse events attributable to natural disease progression or unrelated causes"}]},"_chembl":{"chemblId":"CHEMBL502128","moleculeType":"Small molecule","molecularWeight":"614.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a pharmaceutical formulation containing no active ingredient. It is used in randomized controlled trials to establish baseline efficacy and safety by comparison with active drug treatment, allowing researchers to distinguish true drug effects from placebo response and natural disease progression.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:34.260Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials (specific indication depends on parent trial)"}]},"trialDetails":[{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31},{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06344104","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-08","conditions":"Uncontrolled Hypertension, Resistant Hypertension","enrollment":326},{"nctId":"NCT06412666","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-05-29","conditions":"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","enrollment":55},{"nctId":"NCT07419828","phase":"PHASE3","title":"A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-13","conditions":"Chronic Kidney Disease","enrollment":1978},{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT07497087","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-06-09","conditions":"Systemic Sclerosis","enrollment":448},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT05142735","phase":"NA","title":"Effects of NAC on Symptoms of CHR Patients","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-13","conditions":"Prodromal Schizophrenia","enrollment":90},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14},{"nctId":"NCT06993792","phase":"PHASE3","title":"A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-15","conditions":"Obesity, Overweight, Type 2 Diabetes","enrollment":1200},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224},{"nctId":"NCT06241313","phase":"PHASE3","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-03-25","conditions":"Migraine","enrollment":1300},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT06964776","phase":"PHASE1","title":"A Study of LY4268989 (MORF-057) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-01","conditions":"Healthy","enrollment":144},{"nctId":"NCT06280235","phase":"PHASE2","title":"A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-27","conditions":"Depressive Disorder, Major","enrollment":243},{"nctId":"NCT05501678","phase":"PHASE2","title":"Trial of Diphenhydramine for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT07495995","phase":"PHASE2","title":"Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-04-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","enrollment":94},{"nctId":"NCT01113229","phase":"PHASE4","title":"Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-03","conditions":"Hemorrhage; Complicating Delivery","enrollment":1721},{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT07225504","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-11","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":1275},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT07497880","phase":"PHASE2","title":"Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-04-01","conditions":"Obesity, Overweight","enrollment":320},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT06972459","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-15","conditions":"Obesity, Overweight","enrollment":600},{"nctId":"NCT06679140","phase":"PHASE3","title":"A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-12-08","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":2330},{"nctId":"NCT06082037","phase":"PHASE3","title":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-10-10","conditions":"Lung Transplant Rejection","enrollment":180},{"nctId":"NCT06402123","phase":"PHASE2","title":"A Phase 2b Study of Zagociguat in Patients With MELAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tisento Therapeutics","startDate":"2024-09-10","conditions":"Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)","enrollment":43},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT07493265","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy","status":"NOT_YET_RECRUITING","sponsor":"Eisai Inc.","startDate":"2026-03-23","conditions":"Narcolepsy","enrollment":64},{"nctId":"NCT04394416","phase":"PHASE3","title":"Trial of Imatinib for Hospitalized Adults With COVID-19","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-02","conditions":"COVID-19","enrollment":21},{"nctId":"NCT04026997","phase":"PHASE2","title":"A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis","status":"TERMINATED","sponsor":"CinDome Pharma, Inc.","startDate":"2019-09-11","conditions":"Gastroparesis","enrollment":72},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT07230132","phase":"PHASE2","title":"Efficacy and Safety of ZT006 in Overweight and Obese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","startDate":"2025-12-12","conditions":"Overweight , Obesity","enrollment":184},{"nctId":"NCT07226661","phase":"PHASE2","title":"Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2026-01-19","conditions":"Major Depressive Disorder (MDD)","enrollment":230},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT05312879","phase":"PHASE2, PHASE3","title":"Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-03-30","conditions":"Proteinuric Kidney Disease","enrollment":466},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT06812078","phase":"PHASE2","title":"A Study of TAK-360 in Adults With Idiopathic Hypersomnia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-07","conditions":"Idiopathic Hypersomnia","enrollment":96},{"nctId":"NCT07144163","phase":"PHASE3","title":"A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-12-11","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":150},{"nctId":"NCT07489612","phase":"PHASE2","title":"QLS1410 in Participants With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hypertension (HTN)","enrollment":260},{"nctId":"NCT07388667","phase":"PHASE1","title":"A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT06217302","phase":"PHASE3","title":"Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Alessandro Doria","startDate":"2024-10-31","conditions":"Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1","enrollment":150},{"nctId":"NCT04774159","phase":"PHASE3","title":"Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-05-06","conditions":"Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation","enrollment":6150},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT07489495","phase":"PHASE3","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-17","conditions":"Carcinoma, Renal Cell","enrollment":758},{"nctId":"NCT06655883","phase":"PHASE3","title":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-09","conditions":"Insomnia","enrollment":300},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT05399368","phase":"PHASE2","title":"An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2022-06-07","conditions":"Atopic Dermatitis","enrollment":229},{"nctId":"NCT06637631","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Crohn's Disease","enrollment":260},{"nctId":"NCT06113445","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-29","conditions":"NonSegmental Vitiligo","enrollment":467},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT05452564","phase":"PHASE2","title":"Baricitinib for Reduction of HIV - CNS","status":"RECRUITING","sponsor":"William Tyor","startDate":"2023-05-18","conditions":"Human Immunodeficiency Virus","enrollment":95},{"nctId":"NCT06113471","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-11-27","conditions":"NonSegmental Vitiligo","enrollment":450},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT06547489","phase":"PHASE2","title":"Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2025-02-03","conditions":"Major Depressive Disorder","enrollment":164},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT04781543","phase":"PHASE2","title":"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-11-05","conditions":"Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic","enrollment":301},{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT05431088","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study in Adult and Adolescent Participants With SCD","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-09-22","conditions":"Sickle Cell Disease","enrollment":389},{"nctId":"NCT06667700","phase":"PHASE3","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-02","conditions":"Coronavirus Disease (COVID-19)","enrollment":3082},{"nctId":"NCT07202884","phase":"PHASE3","title":"A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-09-30","conditions":"Urinary Incontinence,Stress","enrollment":1000},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT07367724","phase":"PHASE2","title":"Ademetionine in Obstructive Hypertrophic Cardiomyopathy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-01-01","conditions":"Obstructive Hypertrophic Cardiomyopathy (oHCM)","enrollment":44},{"nctId":"NCT04300920","phase":"PHASE3","title":"Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial","status":"COMPLETED","sponsor":"Fernando J Martinez","startDate":"2020-12-17","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":202},{"nctId":"NCT07044297","phase":"PHASE3","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-31","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4390},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT07486141","phase":"NA","title":"Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capital Medical University","startDate":"2024-11-01","conditions":"Mild Cognitive Impairment","enrollment":380},{"nctId":"NCT05714085","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-31","conditions":"Heart Failure, Left Ventricular Systolic Dysfunction","enrollment":342},{"nctId":"NCT07115329","phase":"PHASE2","title":"A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Syndeio Biosciences, Inc","startDate":"2026-01-05","conditions":"Major Depressive Disorder","enrollment":164},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT07339631","phase":"PHASE1","title":"Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-01","conditions":"Low Back Pain, Paraspinal Muscle, CLBP - Chronic Low Back Pain","enrollment":40},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT07483489","phase":"PHASE2","title":"A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-05-01","conditions":"Refractory Chronic Cough","enrollment":180},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT06340958","phase":"PHASE2","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","status":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","startDate":"2024-03-18","conditions":"Adjunctive Treatment of Major Depressive Disorder (MDD)","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (tablets per os)","genericName":"Placebo (tablets per os)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials. Used for Control arm in phase 3 clinical trials (specific indication depends on parent trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}